Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Halozyme Therapeutics Trading Down 0.7 %

Shares of NASDAQ:HALO opened at $53.46 on Thursday. Halozyme Therapeutics, Inc. has a 52-week low of $32.83 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The company has a market cap of $6.80 billion, a P/E ratio of 22.09, a P/E/G ratio of 0.49 and a beta of 1.27. The stock’s 50-day moving average is $58.80 and its 200-day moving average is $51.04.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.68 earnings per share. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $65.00 price target on shares of Halozyme Therapeutics in a report on Friday, October 4th. Benchmark reissued a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. The Goldman Sachs Group raised their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Morgan Stanley increased their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.44.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. TD Asset Management Inc raised its position in shares of Halozyme Therapeutics by 28.1% during the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares during the last quarter. Congress Asset Management Co. MA increased its stake in Halozyme Therapeutics by 16.2% during the first quarter. Congress Asset Management Co. MA now owns 407,867 shares of the biopharmaceutical company’s stock valued at $16,592,000 after acquiring an additional 56,791 shares during the period. Boston Trust Walden Corp acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at approximately $23,211,000. Los Angeles Capital Management LLC lifted its position in shares of Halozyme Therapeutics by 17.2% in the 1st quarter. Los Angeles Capital Management LLC now owns 121,000 shares of the biopharmaceutical company’s stock worth $4,922,000 after acquiring an additional 17,716 shares during the period. Finally, Norden Group LLC grew its holdings in shares of Halozyme Therapeutics by 1,817.3% during the 1st quarter. Norden Group LLC now owns 167,284 shares of the biopharmaceutical company’s stock worth $6,805,000 after purchasing an additional 158,559 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.